About
Adtrinib is a targeted therapy, likely a tyrosine kinase inhibitor (TKI), employed in the treatment of various cancers. It functions by selectively inhibiting specific protein kinases that are crucial for cell growth, proliferation, and survival, thereby disrupting aberrant signaling pathways that drive cancer progression. This precise, targeted approach aims to slow or halt the growth of malignant cells while potentially minimizing damage to healthy tissues compared to conventional cytotoxic chemotherapies. Adtrinib is typically prescribed for specific types of solid tumors or hematological malignancies where these particular kinase pathways are identified as overactive or mutated. Its efficacy and precise indications are contingent upon the specific molecular targets it inhibits within the cancer cells, often requiring biomarker testing for patient selection.
Uses
- Treatment of specific solid tumors.
- Management of certain hematological malignancies.
- Inhibition of abnormal cell growth pathways.
- Disease progression control in advanced cancers.
Directions For Use
Take orally as directed by your physician, usually once daily, with or without food. Do not crush or chew the tablet.
Benefits
- Targeted action against cancer cells.
- Potential for improved progression-free survival.
- Oral administration convenience.
- May offer an alternative to traditional chemotherapy.
- Effective in specific molecularly defined cancers.
- Helps to control disease progression.
Side Effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Vomiting
- Abdominal pain
- Headache
- Hypertension
- Peripheral edema
- Myelosuppression (low blood counts)
- Elevated liver enzymes
- Stomatitis
Safety Measures
- Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects or interact with the medication, potentially increasing liver strain.
- Pregnancy - Adtrinib is generally contraindicated in pregnancy due to potential fetal harm. Effective contraception is required during treatment and for a period after.
- Breastfeeding - Breastfeeding is not recommended during Adtrinib treatment and for a specified period after the last dose, due to the potential for serious adverse reactions in the infant.
- Liver - Use with caution in patients with pre-existing liver impairment. Dose adjustments may be necessary, and liver function should be monitored regularly.
- Kidney - Use with caution in patients with renal impairment. Dose adjustments may be required based on the degree of kidney dysfunction.
- Lung - Monitor for new or worsening pulmonary symptoms, as interstitial lung disease or pneumonitis can be rare but serious side effects.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!